Abstract
The failure of solid tumors to respond to chemotherapy is a complicated and clinically frustrating issue. The ability to predict which tumors will respond to treatment could reduce the human and monetary costs of cancer therapy by allowing pro-active selection of a chemotherapeutic to which the tumor does not express resistance. PET/CT imaging with a radiolabeled form of paclitaxel, F-18 fluoropaclitaxel (FPAC), may be able to predict the uptake of paclitaxel in solid tumors, and as a substrate of P-glycoprotein, it may also predict which tumors exhibit multidrug resistance (MDR), a phenotype in which tumors fail to respond to a wide variety of chemically unrelated chemotherapeutic agents. This article reviews the synthetic, preclinical and early human data obtained during the development phase of this promising new radiopharmaceutical.
Keywords: Drug development, Molecular Imaging, F-18 fluoropaclitaxel, Multidrug resistance, Paclitaxel, PET, Pgp, PET Imaging, 18F-Fluoropaclitaxel, P-glycoprotein, Tumor cells, chemotherapeutic agent, ABC (ATP Binding Cassette), Pgp expression, Cytochrome p450, Taxus brevifolia, Taxus baccata, Docetaxel, b-tubulin, Phenylisoserine moiety, [99mTc] sestamibi, [99mTc] tetrofosmin, tariquidar, XR9576, microPET, Pgp inhibitor, [18F]FPAC DMSO, Human breast tumor cell line, Standardized uptake value, MCF tumors, MIRDOSE, MDR modulator, Pgp modulation
Current Topics in Medicinal Chemistry
Title: PET Imaging of Multidrug Resistance in Tumors Using 18F-Fluoropaclitaxel
Volume: 10 Issue: 17
Author(s): Karen A. Kurdziel and Dale O. Kiesewetter
Affiliation:
Keywords: Drug development, Molecular Imaging, F-18 fluoropaclitaxel, Multidrug resistance, Paclitaxel, PET, Pgp, PET Imaging, 18F-Fluoropaclitaxel, P-glycoprotein, Tumor cells, chemotherapeutic agent, ABC (ATP Binding Cassette), Pgp expression, Cytochrome p450, Taxus brevifolia, Taxus baccata, Docetaxel, b-tubulin, Phenylisoserine moiety, [99mTc] sestamibi, [99mTc] tetrofosmin, tariquidar, XR9576, microPET, Pgp inhibitor, [18F]FPAC DMSO, Human breast tumor cell line, Standardized uptake value, MCF tumors, MIRDOSE, MDR modulator, Pgp modulation
Abstract: The failure of solid tumors to respond to chemotherapy is a complicated and clinically frustrating issue. The ability to predict which tumors will respond to treatment could reduce the human and monetary costs of cancer therapy by allowing pro-active selection of a chemotherapeutic to which the tumor does not express resistance. PET/CT imaging with a radiolabeled form of paclitaxel, F-18 fluoropaclitaxel (FPAC), may be able to predict the uptake of paclitaxel in solid tumors, and as a substrate of P-glycoprotein, it may also predict which tumors exhibit multidrug resistance (MDR), a phenotype in which tumors fail to respond to a wide variety of chemically unrelated chemotherapeutic agents. This article reviews the synthetic, preclinical and early human data obtained during the development phase of this promising new radiopharmaceutical.
Export Options
About this article
Cite this article as:
A. Kurdziel Karen and O. Kiesewetter Dale, PET Imaging of Multidrug Resistance in Tumors Using 18F-Fluoropaclitaxel, Current Topics in Medicinal Chemistry 2010; 10 (17) . https://dx.doi.org/10.2174/156802610792928077
DOI https://dx.doi.org/10.2174/156802610792928077 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Fc Receptors as a Therapeutic Target
Inflammation & Allergy - Drug Targets (Discontinued) MicroRNAs and the Warburg Effect: New Players in an Old Arena
Current Gene Therapy Tumor Angiogenesis: A Potential Target In Cancer Control by Phytochemicals
Current Cancer Drug Targets Recent Progress of Novel Steroid Derivatives and Their Potential Biological Properties
Mini-Reviews in Medicinal Chemistry Targeting the Ubiquitin-Proteasome Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Magnetic Resonance Nano-Theranostics for Glioblastoma Multiforme
Current Pharmaceutical Design HER2 in the Era of Molecular Medicine: A Review
Current Cancer Therapy Reviews Inhibition of Hyaluronan Synthase-3 Decreases Subcutaneous Colon Cancer Growth by Increasing Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Cells with Minimal Expression of the JAK/STAT Pathway Related Proteins STAT5a and the Prolactin Receptor: Evidence of an Alternate Prolactin Receptor Isoform in Breast Disease
Protein & Peptide Letters Chitosan Nanoparticles for Melanoma Cancer Treatment by Photodynamic Therapy and Electrochemotherapy Using Aminolevulinic Acid Derivatives
Current Medicinal Chemistry Beyond Cox-Inhibition: ‘Side-Effects’ of Ibuprofen on Neoplastic Development and Progression
Current Pharmaceutical Design Medicinal Chemistry of Indolylglyoxylamide TSPO High Affinity Ligands with Anxiolytic-Like Effects
Current Topics in Medicinal Chemistry The Quest to Repair the Damaged Spinal Cord
Recent Patents on CNS Drug Discovery (Discontinued) A Brief Introduction to Porphyrin Compounds used in Tumor Imaging and Therapies
Mini-Reviews in Medicinal Chemistry Breast Cancer: Not Only a “Womans” Disease
Current Women`s Health Reviews Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry Risk Communication of Vaccines: Challenges in the Post-Trust Environment
Current Drug Safety Oncogenomic Approaches in Exploring Gain of Function of Mutant p53
Current Genomics